US voters will head to the polls next week in the midterm elections, and in the run-up to the election, the Kaiser Family Foundation has revealed that pharmaceutical companies have donated nearly $79 million to members of Congress over the past 6 election cycles.
US voters will head to the polls next week in the midterm elections, and in the run-up to the election, the Kaiser Family Foundation has revealed that pharmaceutical companies have, over the past 6 election cycles, donated nearly $79 million to members of Congress.
These findings come from Kaiser’s newly launched “Pharma Cash to Congress” tool, which uses campaign finance reports from the Federal Election Commission. The interactive tool allows users to explore which lawmakers have received the biggest contributions from pharma, and which companies have given the most. Voters can search for members of congress to find detailed breakdowns of contributions received from individual pharmaceutical companies both in the current election cycle and since 2007.
According to Kaiser, since the beginning of 2017, 34 lawmakers have each received more than $100,000 each from drug makers’ political action committees (PACs), and 2 representatives—Kevin McCarthy, R-California, and Greg Walden, R-Oregon, have accepted more than $200,000 each.
More Republicans (209) than Democrats (185) received contributions, with Republican representatives and senators receiving a total of $4.9 million and $2.1 million, respectively, and Democratic representatives and senators receiving $3.3 million and $1.6 million, respectively, as of June 30, 2018. During the 2010 election cycle, when Democrats were in power, a greater amount of donated dollars went to Democratic lawmakers.
Among companies who contributed the most were Pfizer ($1.02 million), Amgen ($946,000), AbbVie ($852,000), and Abbot Laboratories ($703,000).
Kaiser also notes that donations to lawmakers in election cycles tell only part of the story of pharma’s influence in US politics; its “Pre$cription for Power” tool, released in April of this year, tracked donations to patient advocacy groups that, it says, “provide patients to testify on Capitol Hill and organize social media campaigns on drugmakers’ behalf.”
Kaiser’s research into these donatiosn revealed that pharmaceutical companies gave $116 million to patient groups in 2015 alone, raising concerns that patient groups’ advocacy, and eventually the nation’s health policy, could be negatively impacted by pharma’s dollars.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.